The Lab Testing and Related Services (LTS) segment is a core business area for H.U. Group Holdings, providing a wide array of diagnostic testing services to medical institutions. This segment encompasses clinical laboratory testing, including tests for infectious diseases, cancer, and lifestyle diseases. Research and development activities focus on improving the accuracy, speed, and efficiency of diagnostic tests, as well as expanding the range of tests offered. Technologies and methodologies include chemiluminescent enzyme immunoassays (LUMIPULSE), rapid diagnostic kits (ESPRINE), and other advanced testing platforms. The segment addresses a broad range of therapeutic areas, impacting patient outcomes by enabling early and accurate diagnosis. Market positioning is strong in Japan, with a focus on expanding globally. Future opportunities include the development of new tests and services, and the integration of AI and data analytics to improve diagnostic accuracy and efficiency. Partnerships with medical institutions and research organizations are key to this segment's success.

The In Vitro Diagnostics (IVD) segment focuses on the research, development, manufacturing, and sale of in vitro diagnostic devices and reagents. This segment is driven by Fujirebio, a subsidiary of H.U. Group Holdings, and is a global leader in high-quality IVD testing. Research and development efforts are focused on developing innovative diagnostic tools, including the LUMIPULSE system, which offers reagents for various diseases. Technologies and methodologies include chemiluminescence, immunoassays, and rapid diagnostic kits. The therapeutic areas covered include infectious diseases, cancer, and lifestyle diseases. The patient impact is significant, as accurate and timely diagnostics are crucial for effective treatment. Market positioning is strong, with a focus on expanding the product portfolio and geographic reach. Future opportunities include the development of new diagnostic tests and the expansion of partnerships with leading companies. Regulatory compliance and clinical validation are critical aspects of this segment.

This segment provides support services related to hospital administration, including aid for surgical procedures, endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services. It also includes the rental and sale of nursing-care equipment and supplies, as well as home-visit nursing care services. Research and development activities focus on improving the efficiency and effectiveness of these services. Technologies and methodologies include logistics management systems and specialized medical equipment maintenance protocols. The segment supports various healthcare settings, improving patient care and operational efficiency. Market positioning is strong in Japan, with a focus on expanding service offerings. Future opportunities include the integration of digital health technologies and the expansion of home healthcare services. Partnerships with hospitals and healthcare providers are essential for this segment's growth.